PARIS, France—With renal denervation on the cusp of gaining a place in clinical practice for the treatment of hypertension, researchers are looking more closely at other conditions associated with ...

Otsuka Medical Devices Co., Ltd. (Otsuka Medical Devices) and Otsuka Pharmaceutical Co., Ltd. (Otsuka Pharmaceutical) ...

CHICAGO, IL—In the expanded SPYRAL HTN-ON MED trial, renal denervation with the Symplicity Spyral multielectrode catheter (Medtronic) failed to meet its primary endpoint in terms of blood ...

Please provide your email address to receive an email when new articles are posted on . Data show renal denervation safely lowers BP, but some question the durability of effect. Experts continue to ...

On August 22-23, 2023, the FDA will conduct an Advisory Committee Meeting to discuss, make recommendations, and vote on renal denervation devices (e.g., devices indicated to reduce blood pressure in ...

Medtronic is investing in the rollout of the Symplicity Spyral renal denervation procedure, including hiring for new market ...

Please provide your email address to receive an email when new articles are posted on . After many years and multiple trials, two FDA-approved renal denervation systems are now available in the U.S.

Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., announced the commercial launch of the Paradise ultrasound r ...

Renal denervation (RDN) was among the most prevalent and buzzed-about topics pumping up the crowd at this year's European Society of Cardiology (ESC) Congress 2012. And in light of the parade of ...

Medtronic suffered yet another disappointment in its relentless pursuit of bringing renal denervation to market for people living with uncontrolled high blood pressure. There seems to be no question ...